Q-omics provides the consensus-scored MIR99AHG profile across patient tissues and cancer cell-line models. MIR99AHG expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR99AHG is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, MIR99AHG RNA expression shows 19,097 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KIRC, and PDAC as cancer lineages where MIR99AHG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR99AHG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR99AHG survival associations across molecular data types. MIR99AHG RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR99AHG RNA expression–survival associations across cancer types. High MIR99AHG expression shows unfavorable associations in BLCA, but favorable associations in HNSC, UCS, ESCA, ACC and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR99AHG RNA expression.
This table summarizes MIR99AHG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR99AHG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR99AHG shows lower tumor expression in KIRC, HNSC, KICH, KIRP, THCA and UCEC. The KIRC box plot shows higher MIR99AHG RNA expression in normal versus tumor tissue (log2 FC = −1.065, t-test p < 0.001).
This table shows molecular features associated with MIR99AHG in patient tissues and cancer cell lines. In patient samples, MIR99AHG shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
